(1 - 11 from 13
)
Oncology Data Advisor - Moxetumomab Pasudotox-Tdfk for ...
oncdata.com
· Robert Kreitman, MD. Hairy cell leukemia (HCL) comprises only 2% of all leukemias and has limited treatment options. In a phase 3 trial, a team of researchers led by Robert Kreitman, MD, a medical oncologist at the National Cancer Institute, found that moxetumomab pasudotox-tdfk, a recombinant CD22-directed cytotoxin, achieved a high rate of durable response
sorted by relevance / date